DBV Technologies to present VITESSE data at EAACI Congress 2026
DBV Technologies announced positive Phase 3 VITESSE data showing the VIASKIN Peanut Patch's efficacy in children with peanut allergy and comorbid atopic conditions. The company will also preview the Phase 2 THRIVE study design for infants at the EAACI Congress 2026.
*this image is generated using AI for illustrative purposes only.
DBV Technologies will present new positive data from its Phase 3 VITESSE study and the design of its recently initiated Phase 2 THRIVE study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026. The event is scheduled for June 12 – 15, 2026, in Istanbul, Turkey. The presentations focus on the efficacy and safety of the VIASKIN Peanut Patch across different pediatric age groups.
In the Phase 3 VITESSE study, the VIASKIN Peanut Patch demonstrated statistically significant efficacy compared to placebo in children ages 4 through 7 years with peanut allergy. This efficacy was specifically observed in subgroups of children who also had another common atopic condition, such as asthma, concomitant food allergy, or atopic dermatitis.
DBV Technologies will also provide a preview of the clinical trial design for its Phase 2 THRIVE study. This study will assess the efficacy and safety of the VIASKIN Peanut Patch in achieving ad lib consumption of peanuts in infants ages 6 through 12 months with peanut allergy. The assessment will follow three years of treatment.
The following table outlines the key details of the studies being presented:
| Study Name | Phase | Patient Age Group | Key Objective |
|---|---|---|---|
| VITESSE | Phase 3 | 4 through 7 years | Efficacy vs. placebo in subgroups with atopic conditions |
| THRIVE | Phase 2 | 6 through 12 months | Efficacy and safety for ad lib peanut consumption |
Both studies will be featured in oral abstract sessions at the congress.
How will the efficacy data in the 4-7 age subgroup influence regulatory approval strategies for the broader pediatric population?
What are the potential market implications if the Phase 2 THRIVE study successfully enables ad lib consumption in infants?
How might the inclusion criteria focusing on comorbid atopic conditions affect the commercial labeling and target patient base?
19
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
